New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
07:06 EDTENDP, BDSIEndo, BioDelivery Sciences announces positive results from buprenorphine trial
Endo Pharmaceuticals, a subsidiary of Endo International (ENDP) and BioDelivery Sciences (BDSI) announced positive top-line results from its pivotal Phase III efficacy study of BEMA buprenorphine in opioid-experienced patients. The trial successfully met its primary efficacy endpoint in demonstrating that BEMA buprenorphine resulted in significantly improved chronic pain relief compared to placebo. Additional secondary endpoints were supportive of the efficacy of BEMA buprenorphine compared to placebo. The most commonly reported adverse events in patients treated with buprenorphine compared to placebo were nausea and vomiting.
News For ENDP;BDSI From The Last 14 Days
Check below for free stories on ENDP;BDSI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2014
09:26 EDTENDPEndo puts AMS medical-device unit up for sale, WSJ says
Subscribe for More Information
August 22, 2014
09:38 EDTBDSIBioDelivery Sciences sales may jump on DEA move, says Summer Street
Subscribe for More Information
August 19, 2014
07:34 EDTBDSIBioDelivery Sciences management to meet with William Blair
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use